Part 3 of “The Business Model of Healthcare: From Costs to Cures” series Industry-cited averages to “bring a drug to market” often trace to Tufts Center estimates of roughly $2.6 billion (capitalized, 2013$), with some accounting approaches placing the figure higher when company-level R&D is divided by approvals. But a 2025 RAND study in JAMA…
Tag: Healthcare Economics
Analysis of healthcare markets, pricing, and economic policy
